Thieblemont C, Wahlin BE, Mohseninejad L, Wang K, et al. Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma. Leuk Lymphoma 2024 Oct 24:1-10. doi: 10.1080/10428194.2024.2416577.
PMID: 39444341